The role of prolactin/vasoinhibins in cardiovascular diseases

Zhao, Hui; Gong, Shan Shan; Shi, Yongcong; Luo, Ci‐Jun; Qiu, Hong‐Ling; He, Jing; Sun, Yuanyuan; Huang, Yuxia; Wang, Shang; Miao, Yuqing; Wu, Wenhui

doi:10.1002/ame2.12264

Cited by 5 publications

(3 citation statements)

References 93 publications

(250 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PRL is a pleiotropic hormone for its regulation in metabolic and immune homeostasis and inflammatory response. 29 For example, PRL plays an important role in regulating insulin secretion and glucose homeostasis. 30 Similar to PRL, Nrg4 plays an important role in various metabolic diseases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neuregulin 4 (Nrg4) cooperates with melatonin to regulate the PRL expression via ErbB4/Erk signaling pathway as a potential prolactin (PRL) regulator

Lin,

Ou,

Dai

et al. 2024

J of Cellular Biochemistry

View full text Add to dashboard Cite

Neuregulin‐4 (Nrg4) and melatonin play vital roles in endocrine diseases. However, there is little discussion about the function and potential mechanism of Nrg4 and melatonin in prolactin (PRL) regulation. The human normal pituitary data from Gene Expression Profiling Interactive Analysis (GEPIA) database was used to explore the correlation between NRG4 and PRL. The expression and correlation of NRG4 and PRL were determined by Immunofluorescence staining (IF) and human normal pituitary tissue microarray. Western Blot (WB) was used to detect the expression of PRL, p‐ErbB2/3/4, ErbB2/3/4, p‐Erk1/2, Erk1/2, p‐Akt and Akt in PRL‐secreting pituitary GH3 and RC‐4B/C cells treated by Nrg4, Nrg4‐small interfering RNA, Erk1/2 inhibitor FR180204 and melatonin. The expression of NRG4 was significantly positively correlated with that of PRL in the GEPIA database and normal human pituitary tissues. Nrg4 significantly increased the expression and secretion of PRL and p‐Erk1/2 expression in GH3 cells and RC‐4B/C cells. Inhibition of Nrg4 significantly inhibited PRL expression. The increased levels of p‐Erk1/2 and PRL induced by Nrg4 were abolished significantly in response to FR180204 in GH3 and RC‐4B/C cells. Additionally, Melatonin promotes the expression of Nrg4, p‐ErbB4, p‐Erk1/2, and PRL and can further promote the expression of p‐Erk1/2 and PRL in combination with Nrg4. Further investigation into the function of Nrg4 and melatonin on PRL expression and secretion may provide new clues to advance the clinical control of prolactinomas and hyperprolactinemia.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Therefore, it is necessary to explore the key genes regulating PRL and search for their potential regulatory mechanisms. PRL is a pleiotropic hormone for its regulation in metabolic and immune homeostasis and inflammatory response 29 . For example, PRL plays an important role in regulating insulin secretion and glucose homeostasis 30 .…”

Section: Discussionmentioning

confidence: 99%

Neuregulin 4 (Nrg4) cooperates with melatonin to regulate the PRL expression via ErbB4/Erk signaling pathway as a potential prolactin (PRL) regulator

Lin,

Ou,

Dai

et al. 2024

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…When PRL binds to PRLR, it causes receptor dimerization, resulting in the initiation of several intracellular signal transduction, including canonical Janus kinase 2/signal transducer and activator of transcription (JAK2/STAT) pathway, MAPK pathway, and phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) pathway. [ 38 ] JAK2 is a non-receptor tyrosine kinase that is rapidly activated upon stimulation with PRL, promoting the phosphorylation and nuclear localization of STATs, including STAT3 and STAT5. [ 39 ] The JAK2/STAT3 pathway is an extremely important intracellular signal transduction pathway that has been widely recognized as a critical modulator of a variety of biological processes, including innate and adaptive immunity and inflammation.…”

Section: Discussionmentioning

confidence: 99%

Network pharmacology and molecular docking reveal potential mechanism of esculetin in the treatment of ulcerative colitis

Cai,

Cai

2023

Medicine

View full text Add to dashboard Cite

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colonic mucosa. Esculetin is a type of natural coumarin that has many pharmacological activities such as antioxidant, anticancer, anti-inflammatory, etc. A previous study showed that esculetin improved intestinal inflammation and reduced serum proinflammatory cytokines in UC. The present study aimed to utilize network pharmacology and molecular docking to explore the potential mechanism of esculetin against UC. The potential gene targets of esculetin were predicted through SwissTargetPrediction and Super-PRED web servers. UC-related genes were obtained from DisGeNet, OMIM, and GeneCards databases. The overlap between gene targets of esculetin and UC-related genes were identified as the potential targets of esculetin against UC. The interaction between these overlapping genes was analyzed by the STRING database and the core genes were identified by Cytoscape platform. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of the core genes were then performed. And the results of these analyses were further confirmed through molecular docking. A total of 50 overlapping genes were identified as the potential action targets of esculetin against UC. Among them, 10 genes (AKT1, STAT1, CCND1, SRC, PTGS2, EGFR, NFKB1, ESR1, MMP9, SERPINE1) were finally identified as the core genes. The Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis results showed that the top signaling pathway associated with the core genes of esculetin against UC was the prolactin (PRL) signaling pathway. Molecular docking results showed that esculetin has a strong binding affinity to the core genes, as well as PRL and prolactin receptor. This study suggests that esculetin may have a crucial impact on UC through the PRL signaling pathway and provides insights into the potential mechanism of esculetin in the treatment of UC, which may shed light on the mechanism and treatment of UC.

show abstract

The role of prolactin/vasoinhibins in cardiovascular diseases

Zhao

Gong

Shi³

et al. 2022

Anim Models and Exp Med

Self Cite

View full text Add to dashboard Cite

Prolactin (PRL) is a polypeptide hormone that is mainly synthesized and secreted by the lactotroph cells of the pituitary. There are two main isoforms of PRL: 23‐kDa PRL (named full‐length PRL) and vasoinhibins (including 5.6–18 kDa fragments). Both act as circulating hormones and cytokines to stimulate or inhibit vascular formation at different stages and neovascularization, including endothelial cell proliferation and migration, protease production, and apoptosis. However, their effects on vascular function and cardiovascular diseases are different or even contrary. In addition to the structure, secretion regulation, and signal transduction of PRL/vasoinhibins, this review focuses on the pathological mechanism and clinical significance of PRL/vasoinhibins in cardiovascular diseases.

show abstract

The role of prolactin/vasoinhibins in cardiovascular diseases

Cited by 5 publications

References 93 publications

Neuregulin 4 (Nrg4) cooperates with melatonin to regulate the PRL expression via ErbB4/Erk signaling pathway as a potential prolactin (PRL) regulator

Neuregulin 4 (Nrg4) cooperates with melatonin to regulate the PRL expression via ErbB4/Erk signaling pathway as a potential prolactin (PRL) regulator

Network pharmacology and molecular docking reveal potential mechanism of esculetin in the treatment of ulcerative colitis

The role of prolactin/vasoinhibins in cardiovascular diseases

Contact Info

Product

Resources

About